ArticleJournal of ovarian research2025
Functional study of laminin subunit α5 in high-grade serous ovarian cancer.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diversity within ovarian cancer subtypes and their tumor microenvironment.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of LAMA 5 (laminin subunit α5) in high-grade serous ovarian cancer and its relationship with the prognosis of ovarian cancer patients.
methodsThe expression of LAMA5 in high-grade serous ovarian cancer was explored through the ovarian cancer sample information in multiple databases and real-time fluorescent quantitative PCR (Real Time Quantitative PCR, RT-qPCR). Effect of LAMA5 on the proliferation and migration of ovarian cancer cells. The possible mechanism of LAMA 5 affecting the malignant process of ovarian cancer was searched by GSEA analysis.
resultsBased on bioinformatics analysis and RT-qPCR verification in multiple databases, it was found that LAMA5 was highly expressed in serous ovarian cancer, which was related to clinical stage and indicated poor prognosis. High expression of LAMA 5 can promote the proliferation and migration of ovarian cancer cells. Based on the GSEA analysis, it is suggested that the process of LAMA5 promoting the occurrence and development of ovarian cancer may be related to the mitotic pathway of the spindle (Mitotic Spindle) and the Hedgehog (Hh) signaling pathway.
conclusionLAMA 5 may be used as a clinical marker for evaluating the prognosis of serous ovarian cancer and a new therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.